CONTEXT: The prognosis of appendiceal goblet cell carcinoid tumors (GCTs) is believed to be intermediate between appendiceal adenocarcinomas and conventional carcinoid tumors. However, GCTs can have mixed morphologic patterns, with variable amount of adenocarcinoma. OBJECTIVE: To evaluate the behavior of GCTs and related entities with variable components of adenocarcinoma. DESIGN: We classified 74 cases of appendiceal tumors into 3 groups: group 1, GCTs or GCTs with less than 25% adenocarcinoma; group 2, GCTs with 25% to 50% adenocarcinoma; group 3, GCTs with more than 50% adenocarcinoma; and a comparison group of 68 adenocarcinomas without a GCT component (group 4). Well-differentiated mucinous adenocarcinomas were excluded. Clinicopathologic features and follow-up were obtained from computerized medical records and the US Social Security Death Index. RESULTS: Of the 142 tumors studied, 23 tumors (16%) were classified as group 1; 27 (19%) as group 2; 24 (17%) as group 3; and 68 (48%) as group 4. Staging and survival differed significantly among these groups. Among 140 patients (99%) with available staging data, stages II, III, and IV were present in 87%, 4%, and 4% of patients in group 1 patients; 67%, 7%, and 22% of patients in group 2; 29%, 4%, and 67% of patients in group 3; and 19%, 6%, and 75% of patients in group 4, respectively (P = .01). Mean (SD) overall survival was 83.8 (34.6), 60.6 (30.3), 45.6 (39.7), and 33.6 (27.6) months for groups 1, 2, 3, and 4, respectively (P = .01). By multivariate analysis, only stage and tumor category were independent predictors of overall survival. CONCLUSION: Our data highlight the importance of subclassifying the proportion of adenocarcinoma in appendiceal tumors with GCT morphology because that finding reflects disease stage and affects survival.
CONTEXT: The prognosis of appendiceal goblet cell carcinoid tumors (GCTs) is believed to be intermediate between appendiceal adenocarcinomas and conventional carcinoid tumors. However, GCTs can have mixed morphologic patterns, with variable amount of adenocarcinoma. OBJECTIVE: To evaluate the behavior of GCTs and related entities with variable components of adenocarcinoma. DESIGN: We classified 74 cases of appendiceal tumors into 3 groups: group 1, GCTs or GCTs with less than 25% adenocarcinoma; group 2, GCTs with 25% to 50% adenocarcinoma; group 3, GCTs with more than 50% adenocarcinoma; and a comparison group of 68 adenocarcinomas without a GCT component (group 4). Well-differentiated mucinous adenocarcinomas were excluded. Clinicopathologic features and follow-up were obtained from computerized medical records and the US Social Security Death Index. RESULTS: Of the 142 tumors studied, 23 tumors (16%) were classified as group 1; 27 (19%) as group 2; 24 (17%) as group 3; and 68 (48%) as group 4. Staging and survival differed significantly among these groups. Among 140 patients (99%) with available staging data, stages II, III, and IV were present in 87%, 4%, and 4% of patients in group 1 patients; 67%, 7%, and 22% of patients in group 2; 29%, 4%, and 67% of patients in group 3; and 19%, 6%, and 75% of patients in group 4, respectively (P = .01). Mean (SD) overall survival was 83.8 (34.6), 60.6 (30.3), 45.6 (39.7), and 33.6 (27.6) months for groups 1, 2, 3, and 4, respectively (P = .01). By multivariate analysis, only stage and tumor category were independent predictors of overall survival. CONCLUSION: Our data highlight the importance of subclassifying the proportion of adenocarcinoma in appendiceal tumors with GCT morphology because that finding reflects disease stage and affects survival.
Authors: M I Prieto-Nieto; D Pastor; J Rodríguez-Cobos; J P Pérez; C Méndez; E Palacios; M Arranz-Alvarez; J Santos-López; M Cano-Vega; D Viñal; N Rodríguez; G Domínguez Journal: Clin Transl Oncol Date: 2019-10 Impact factor: 3.405
Authors: Hiroyuki Arai; Yasmine Baca; Francesca Battaglin; Natsuko Kawanishi; Jingyuan Wang; Shivani Soni; Wu Zhang; Joshua Millstein; Curtis Johnston; Richard M Goldberg; Philip A Philip; Andreas Seeber; Joanne Xiu; Jimmy J Hwang; Anthony F Shields; John L Marshall; W Michael Korn; Heinz-Josef Lenz Journal: Mol Cancer Ther Date: 2020-10-09 Impact factor: 6.261
Authors: Moritz Jesinghaus; Björn Konukiewitz; Sebastian Foersch; Albrecht Stenzinger; Katja Steiger; Alexander Muckenhuber; Claudia Groß; Martin Mollenhauer; Wilfried Roth; Sönke Detlefsen; Wilko Weichert; Günter Klöppel; Nicole Pfarr; Anna Melissa Schlitter Journal: Mod Pathol Date: 2018-01-12 Impact factor: 7.842
Authors: Edward Alabraba; David Mark Pritchard; Rebecca Griffin; Rafael Diaz-Nieto; Melissa Banks; Daniel James Cuthbertson; Stephen Fenwick Journal: Endocrine Date: 2021-04-23 Impact factor: 3.633
Authors: Michelle D Reid; Olca Basturk; Walid L Shaib; Yue Xue; Serdar Balci; Hye-Jeong Choi; Gizem Akkas; Bahar Memis; Brian S Robinson; Bassel F El-Rayes; Charles A Staley; Christopher A Staley; Joshua H Winer; Maria C Russell; Jessica H Knight; Michael Goodman; Alyssa M Krasinskas; Volkan Adsay Journal: Mod Pathol Date: 2016-06-24 Impact factor: 7.842